Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.
暂无分享,去创建一个
C B Granger | M. Pfeffer | R. Califf | S. Yusuf | J. McMurray | K. Swedberg | J. Rouleau | C. Granger | E. Michelson | M. A. Sellers | L. Stevenson | A. Maggioni | G. Ertl | P. Held | James B. Young | B. Bart | J. Kuch | M A Pfeffer | E L Michelson | B A Bart | G Ertl | P Held | J Kuch | A P Maggioni | J McMurray | J L Rouleau | L Warner Stevenson | K Swedberg | J B Young | S Yusuf | M A Sellers | R M Califf | A. Maggioni | R. Califf | J. Young | L. Warner Stevenson | G. Ertl
[1] W. Hall,et al. Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy , 1992, Annals of Internal Medicine.
[2] J. Wei,et al. Age and the cardiovascular system. , 1992, The New England journal of medicine.
[3] Mark A. Hlatky,et al. Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .
[4] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[5] E. Philbin,et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.
[6] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[7] H. Krause-Steinrauf,et al. Where are all the women with heart failure? , 1997, Journal of the American College of Cardiology.
[8] Investigators Seosi. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. SEOSI Investigators. , 1997, European heart journal.
[9] S. Yusuf,et al. Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. , 1992, The American journal of cardiology.
[10] J. Cohn,et al. Effect of Enalapril, Hydralazine Plus Isosorbide Dinitrate, and Prazosin on Hospitalization in Patients With Chronic Congestive Heart Failure , 1993, Circulation.
[11] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[12] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[13] C M O'Connor,et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. , 1997, Journal of the American College of Cardiology.
[14] S. Yusuf,et al. Natural history and patterns of current practice in heart failure , 1993 .
[15] D. Levy,et al. Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.
[16] S. Yusuf,et al. Patterns of Medication Use in Patients With Heart Failure: A Report From the Registry of Studies of Left Ventricular Dysfunction (SOLVD) , 1995, Southern medical journal.
[17] B. Massie,et al. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.
[18] S. Fortmann,et al. Differences in treatment of acute myocardial infarction by sex, age, and other factors (the Stanford Five-City Project). , 1996, The American journal of cardiology.
[19] R. Carney,et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.
[20] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[21] D. Blumenthal,et al. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. , 1997, Archives of internal medicine.
[22] W. Stevenson,et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. , 1995, Journal of the American College of Cardiology.
[23] J. Hampton,et al. Evidence of inadequate investigation and treatment of patients with heart failure. , 1994, British heart journal.
[24] G. Hillis,et al. Changing patterns of investigation and treatment of cardiac failure in hospital. , 1996, Heart.
[25] J. Cohn,et al. The management of chronic heart failure. , 1996, The New England journal of medicine.
[26] W. Rogers,et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). , 1993, JAMA.
[27] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[28] B. Psaty,et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.
[29] R. Califf,et al. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. , 1997, The American journal of cardiology.
[30] M. Pfeffer,et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. , 1991, The New England journal of medicine.
[31] S. Reis,et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. , 1997, Journal of the American College of Cardiology.
[32] R. Doughty,et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.
[33] C M O'Connor,et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.
[34] J Z Ayanian,et al. Differences in the use of procedures between women and men hospitalized for coronary heart disease. , 1991, The New England journal of medicine.
[35] L Pilote,et al. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, The New England journal of medicine.
[36] M. Pfeffer,et al. Beta-adrenergic blockers and survival in heart failure. , 1996, The New England journal of medicine.
[37] Y Wang,et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.
[38] H. Doval,et al. Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.
[39] C. Nelson,et al. Left Ventricular Function in Hospitalized Geriatric Patients , 1982, Journal of the American Geriatrics Society.
[40] S. Yusuf,et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. , 1994, American heart journal.
[41] K. Bailey,et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. , 1993, Mayo Clinic proceedings.
[42] Eli Warnock,et al. The effect of diltiazem on mortality and reinfarction after myocardial infarction. , 1989, The New England journal of medicine.
[43] P E Leaverton,et al. Prevalence and mortality rate of congestive heart failure in the United States. , 1992, Journal of the American College of Cardiology.
[44] G. Lamas,et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. , 1992, The New England journal of medicine.
[45] C. O'connor,et al. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. , 1997, The American journal of cardiology.
[46] M B Weiss,et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. , 1996, American heart journal.